Eli Lilly and Company to Acquire Verve Therapeutics for Up to $1.3 Billion
June 17, 2025
Major RNA & Gene Editing Milestone – Eli Lilly and Company to Acquire Verve Therapeutics for Up to $1.3 Billion
Eli Lilly is set to acquire Verve Therapeutics, , a leader in gene editing and cardiovascular RNA therapies, in a deal valued up to $1.3B. This bold move reflects growing confidence in RNA-guided gene editing as a transformative therapeutic approach—particularly for hard-to-treat cardiovascular diseases.
Verve’s pipeline includes single-course gene editing treatments targeting PCSK9 and ANGPTL3—key regulators of cholesterol metabolism.
A major signal to the biotech community: the RNA-based therapeutics and gene editing space continues to attract strong investment and strategic interest from pharma giants.
